TRVI Profile
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical firm, is dedicated to advancing therapies for severe neurologically mediated disorders. The company's lead product, Haduvio, is an oral extended-release formulation of nalbuphine currently undergoing Phase IIb/III clinical trials. Haduvio is being evaluated for its efficacy in treating chronic pruritus, a debilitating itching condition, and chronic cough associated with idiopathic pulmonary fibrosis (IPF), a progressive lung disease.
Trevi Therapeutics' development pipeline primarily focuses on leveraging nalbuphine’s unique properties to address unmet medical needs in the realm of chronic neurological and inflammatory conditions. The company's clinical trials aim to validate Haduvio's potential benefits in managing symptoms that are not adequately addressed by current therapies. This includes investigating its impact on patient quality of life and functional outcomes in chronic pruritus and cough.
The company holds a strategic license agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and commercialize products containing nalbuphine hydrochloride across various formulations. This partnership is integral to Trevi Therapeutics' strategy for expanding its therapeutic offerings and accelerating the development of its pipeline assets.
Founded in 2011 and headquartered in New Haven, Connecticut, Trevi Therapeutics continues to build on its expertise in neurology and chronic disease management. The company’s focus remains on innovating solutions that address complex and often underserved medical conditions, positioning itself as a key player in the biopharmaceutical sector dedicated to improving patient outcomes.
|
